Monday, February 16, 2026 2/16/2026

A new highly sensitive targeted imaging method for early tumor detection

Award Number: R21CA274007
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/08/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2026

Group Awards By:

View Award Description

A new highly sensitive targeted imaging method for early tumor detection - SUMMARY The project is aimed at the development of a new highly sensitive multi-tumor type imaging procedure. The imaging is based on a marker of the tumor blood vessels, the Follicle Stimulating Hormone Receptor (FSHR), which was shown by us to be present in all major cancer types and at all stages, advanced and incipient. The first Aim is to assemble the imaging agents and to test them in cell cultures. Anti-FSHR antibodies will be labeled with imaging agents, tested for binding to cells in culture that produce FSHR and will be optimized by selecting the best antibodies. The second Aim is to test the performance of the imaging agents in mice. The imaging agents will be delivered by intravenous injection in mice that carry tumors formed by implanting human tumor cells and the tumors will be imaged. A tumor cell line that generate metastatic lesions in mice will be used to determine the smallest tumor size that can be detected. Tumors will be analyzed in parallel by immunohistochemistry in tissue sections, in order to determine the yield and sensitivity of detection by imaging. The procedure can contribute to a national priority in cancer research – to reduce substantially cancer mortality by early detection of asymptomatic tumors. Early detection increases substantially the chance of successful therapy, and significantly reduces the overall cost of cancer treatment. The method could be initially tested for periodic screening of patients who are at high risk of developing cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $191,337 )
2024	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	2	4/25/2024	NON-COMPETING CONTINUATION	$191,337
														Subtotal = $191,337

Issue Date FY: 2023 ( Subtotal = $258,238 )
2023	2023	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	1	5/4/2023	NEW	$258,238
														Subtotal = $258,238

Grand Total All Awards = $449,575

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A new highly sensitive targeted imaging method for early tumor detection

Award Number: R21CA274007

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/08/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer